Gainers
- Liminatus Pharma LIMN shares moved upwards by 91.2% to $24.3 during Thursday's pre-market session. The company's market cap stands at $649.1 million.
- Kronos Bio KRON shares rose 26.65% to $0.85. The company's market cap stands at $52.1 million.
- SILO Pharma SILO shares increased by 23.69% to $0.71. The company's market cap stands at $5.0 million.
- Regencell Bioscience RGC stock rose 22.2% to $770.0. The market value of their outstanding shares is at $10.0 billion.
- Applied DNA Sciences APDN stock rose 16.84% to $6.45. The company's market cap stands at $2.7 million.
- Context Therapeutics CNTX shares increased by 12.98% to $0.65. The company's market cap stands at $58.3 million.
Losers
- Helius Medical Tech HSDT shares fell 76.7% to $0.76 during Thursday's pre-market session.
- Cibus CBUS stock fell 37.29% to $1.48. The company's market cap stands at $48.3 million.
- Kairos Pharma KAPA shares declined by 11.8% to $0.46. The company's market cap stands at $7.7 million.
- Senti Biosciences SNTI shares fell 11.51% to $3.0. The market value of their outstanding shares is at $78.2 million.
- Athira Pharma ATHA shares fell 9.1% to $0.3. The market value of their outstanding shares is at $11.7 million.
- Cognition Therapeutics CGTX shares fell 8.98% to $0.28. The market value of their outstanding shares is at $17.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
APDNApplied DNA Sciences Inc
$3.35-3.18%
Edge Rankings
Momentum
0.21
Growth
15.41
Quality
N/A
Value
95.90
Price Trend
Short
Medium
Long
ATHAAthira Pharma Inc
$0.4016-2.05%
CBUSCibus Inc
$1.384.55%
CGTXCognition Therapeutics Inc
$2.70-15.1%
CNTXContext Therapeutics Inc
$0.88861.80%
HSDTHelius Medical Technologies Inc
$6.20-0.40%
KAPAKairos Pharma Ltd
$1.17-4.89%
LIMNLiminatus Pharma Inc
$3.33-2.06%
RGCRegencell Bioscience Holdings Ltd
$12.935.29%
SILOSILO Pharma Inc
$0.64500.77%
SNTISenti Biosciences Inc
$1.57-0.94%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.